Final results: BTX in the last 18 months has received cumulative total proceeds of $24.2M from exercises of warrants that expired 11/1/10.
- A remaining 24,976 common share purchase warrants expired unexercised;
- BTX now has approximately $32M of cash on hand on a consolidated basis.
BTX plans to use the capital raised through the warrant exercises to strengthen its working capital reserves and for the expansion of its stem cell product development including product development being undertaken at its subsidiaries: Embryome Sciences, Inc., OncoCyte Corporation, OrthoCyte Corporation, BioTime Asia, Limited and ES Cell International Pte Ltd each focused on individual medical applications of stem cell technology.
- Remember, the listing symbol has changed from AMEX: BTIM … to … AMEX: BTX.